SELECT-MONOTHERAPY Long-Term Extension: Phase III Trial of Upadacitinib in Patients With Rheumatoid Arthritis

APLAR 2019: Brisbane, Australia; April 8-11, 2019; JCR: Kyoto, Japan; April 15-17, 2019
EULAR: Madrid, Spain; June 12-15, 2019
Monotherapy with the investigational JAK1 inhibitor upadacitinib showed sustained clinical improvements and safety outcomes through 48 weeks in patients with RA with inadequate response to methotrexate.
Format: Microsoft PowerPoint (.ppt)
File Size: 192 KB
Released: June 24, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Gilead Sciences
Lilly
Sanofi Genzyme and Regeneron Pharmaceuticals

Related Content

Clinical Care Options commentary: Jasvinder Singh provides expert guidance on the use of newer biologic and targeted synthetic DMARDs as monotherapy for rheumatoid arthritis.

Jasvinder Singh, MD, MPH Released: August 2, 2018

Expert physician, nurse, and pharmacist views on using monotherapy to treat rheumatoid arthritis are provided in this CME/CE/CPE-certified video.

Jonathan Scott Coblyn, MD
Program Director
Jessica Farrell, PharmD Frances Griffin, RN, BSN
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 29, 2018 Expiration: June 28, 2019

Expert commentary from Roy Fleischmann, MD, on when to select biologic or targeted synthetic DMARD monotherapy for treating rheumatoid arthritis.

Roy Fleischmann, MD Released: June 8, 2018

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?